BioChemics snags patent for dermal penetration; Experimental therapy crosses blood-brain barrier;

> BioChemics won a patent for its Bifunctional Synthetic Molecule, which is a combination of molecules designed to enhance dermal penetration and efficacy of drugs. Release

> Researchers have developed a delivery system for crossing the blood-brain barrier to treat neurological lysosomal storage disease in mice, a condition that can be fatal for humans. Release

> Noven Pharmaceuticals launched its Minivelle transdermal estrogen patch, the smallest one to deliver plant-based estrogen to treat symptoms of menopause such as hot flashes and night sweats. Release

> Antisense drugs, those designed to restrict the expression of certain genetic traits, are difficult to direct. But researchers in Oregon are looking to overcome the challenge of delivering the drugs to certain target cells. Journal Article

> Researchers at the University of Michigan have found that, although nanoparticles promise better delivery of drugs, they have a hard time leaving the bloodstream once there. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.